Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

Cambridge Health Alliance

Status: Suspended

Conditions: Opioid-use Disorder; Opioid-Related Disorders; Acceptability of Health Care

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT05121428

R01CA229355 (U.S. NIH Grant/Contract)

3R33AT010125 (U.S. NIH Grant/Contract)

CHA-IRB-1179/03/21

Details and patient eligibility

About

This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

Full description

The primary objective of this study is to better understand patients' attitudes and experiences during office-based opioid treatment (OBOT) in the COVID-19 pandemic. This study specifically aims to evaluate attitudes and experiences of people prescribe buprenorphine across five domains with the hope of evaluating a) whether telemedicine has improved their access to and experiences with OBOT; b) the factors that motivate individuals in OBOT to abstain from opioid drug use; c) how patients' view the use of cannabis, benzodiazepines, and nicotine during OBOT; d) the degree to which patients in OBOT report using cannabis, benzodiazepines, and nicotine and how their use might have changed during the COVID-19 pandemic; and e) whether patients attitudes towards cannabis, benzodiazepines, and cigarettes/e-cigarettes are associated with their use of those same substances.

Enrollment: 817 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participants must be 18 years of age or older.
• Participants report currently having a legal prescription for buprenorphine for opioid use disorder.
• Participants must have a past or present opioid use disorder.
• Participants must currently reside in the state of Massachusetts.
• Participants must be able to comprehend the English language.

Exclusion criteria

• Unable to complete an online survey.
• Unable to complete a verification step that ensures bots are not used to complete survey.
• Complete a survey with no variation suggesting they did not read the survey.

Trial design

817 participants in 5 patient groups

Survey 1

Description:

Survey investigating patients' experiences with buprenorphine treatment for Opioid Use Disorder before and during the COVID-19 pandemic

Survey 2

Description:

Survey investigating the factors that motivate patients to abstain from opioid drug use during buprenorphine treatment for Opioid Use Disorder

Survey 3

Description:

Survey investigating patients' attitudes towards and experiences with cannabis use during buprenorphine treatment for Opioid Use Disorder.

Survey 4

Description:

Survey investigating patients' attitudes towards and experiences with cigarettes and e-cigarettes use during buprenorphine treatment for Opioid Use Disorder.

Survey 5

Description:

Survey investigating patients' attitudes towards and experiences with benzodiazepine use during buprenorphine treatment for Opioid Use Disorder.